Literature DB >> 2429193

Effects of acute and chronic phenelzine on regional monoamine metabolism in rats and its potentiation by deuterium substitution.

A V Juorio, A J Greenshaw, A A Boulton.   

Abstract

Phenelzine is a monoamine oxidase inhibitor with antidepressant properties. The present study investigated effects of acute (1-2 mg kg-1 4 h s.c.) and chronic (0.25-2 mg kg-1 day-1 Alzet miniosmotic pumps, 13 days s.c.) administration of phenelzine on regional monoamine metabolism in rats. The effects of these phenelzine treatments were compared with those of equivalent doses of a deuterated form of the drug (phenelzine-d4). The following brain regions and compounds were assessed using high performance liquid chromatography with electrochemical detection: Striatum: dopamine, DOPAC, HVA, 5-HT, 5-HIAA; hypothalamus: dopamine, 5-HT, 5-HIAA, noradrenaline; hippocampus: 5-HT, 5-HIAA, noradrenaline; frontal cortex: dopamine, noradrenaline, 5-HT, 5-HIAA. Acute drug administration increased levels of dopamine, 5-HT and noradrenaline with the exception of dopamine in the hypothalamus and frontal cortex and 5-HT in the hypothalamus. DOPAC, HVA and 5-HIAA levels were decreased. After chronic administration amine levels increased with the exception of dopamine administration amine levels increased with the exception of dopamine in the hypothalamus. The respective acid metabolites were also decreased. These effects of phenelzine were markedly potentiated by deuterium which was substituted for hydrogen in the side chain. The potentiation of these effects was enhanced with chronic administration, differences between phenelzine and phenelzine-d4 effects being more marked at lower doses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429193     DOI: 10.1007/bf00512936

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  9 in total

1.  In vivo-inhibition of serotonin synthesis in mouse brain by beta-phenylethylhydrazine, an inhibitor of monoamine oxidase.

Authors:  B DUBNICK; G A LEESON; G E PHILLIPS
Journal:  Biochem Pharmacol       Date:  1962-01       Impact factor: 5.858

Review 2.  Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs.

Authors:  N H Neff; H Y Yang
Journal:  Life Sci       Date:  1974-06-01       Impact factor: 5.037

3.  The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial.

Authors:  D S Robinson; A Nies; C L Ravaris; K R Lamborn
Journal:  Arch Gen Psychiatry       Date:  1973-09

4.  Use of phenelzine in continuation therapy.

Authors:  J Davidson; D Raft
Journal:  Neuropsychobiology       Date:  1984       Impact factor: 2.328

5.  Potentiation of the behavioural effects of the antidepressant phenelzine by deuterium substitution.

Authors:  C T Dourish; K M Dewar; L E Dyck; A A Boulton
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

6.  A multiple-dose, controlled study of phenelzine in depression-anxiety states.

Authors:  C L Ravaris; A Nies; D S Robinson; J O Ives; K R Lamborn; L Korson
Journal:  Arch Gen Psychiatry       Date:  1976-03

7.  Rapid automated analysis of biogenic amines and their metabolites using reversed-phase high-performance liquid chromatography with electrochemical detection.

Authors:  C F Saller; A I Salama
Journal:  J Chromatogr       Date:  1984-08-10

8.  Potentiation of the biochemical effects of beta-phenylethylhydrazine by deuterium substitution.

Authors:  L E Dyck; D A Durden; P H Yu; B A Davis; A A Boulton
Journal:  Biochem Pharmacol       Date:  1983-05-01       Impact factor: 5.858

9.  Inhibition of aromatic L-amino acid decarboxylase and tyrosine aminotransferase by the monoamine oxidase inhibitor phenelzine.

Authors:  L E Dyck; K M Dewar
Journal:  J Neurochem       Date:  1986-06       Impact factor: 5.372

  9 in total
  4 in total

Review 1.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 2.  Ovarian steroids and serotonin neural function.

Authors:  C L Bethea; M Pecins-Thompson; W E Schutzer; C Gundlah; Z N Lu
Journal:  Mol Neurobiol       Date:  1998-10       Impact factor: 5.590

3.  The origin of palmitic acid in brain of the developing rat.

Authors:  B N Marbois; H O Ajie; R A Korsak; D K Sensharma; J Edmond
Journal:  Lipids       Date:  1992-08       Impact factor: 1.880

4.  Effect of chronic deuterated and non-deuterated phenelzine on rat brain monoamines and monoamine oxidase.

Authors:  L E Dyck; A V Juorio; D A Durden; A A Boulton
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-03       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.